| Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer SJ Antonia, A Villegas, D Daniel, D Vicente, S Murakami, R Hui, T Yokoi, ... New England Journal of Medicine 377 (20), 1919-1929, 2017 | 4088 | 2017 |
| Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC SJ Antonia, A Villegas, D Daniel, D Vicente, S Murakami, R Hui, T Kurata, ... New England Journal of Medicine 379 (24), 2342-2350, 2018 | 2645 | 2018 |
| Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small … H West, M McCleod, M Hussein, A Morabito, A Rittmeyer, HJ Conter, ... The Lancet Oncology 20 (7), 924-937, 2019 | 1387 | 2019 |
| Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study MC Garassino, BC Cho, JH Kim, J Mazières, J Vansteenkiste, H Lena, ... The Lancet Oncology 19 (4), 521-536, 2018 | 547 | 2018 |
| Randomized phase II trial of onartuzumab in combination with erlotinib in patients with advanced non–small-cell lung cancer DR Spigel, TJ Ervin, RA Ramlau, DB Daniel, JH Goldschmidt Jr, ... Journal of clinical oncology 31 (32), 4105, 2013 | 521 | 2013 |
| Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non–small cell lung cancer NB Leighl, RD Page, VM Raymond, DB Daniel, SG Divers, KL Reckamp, ... Clinical cancer research 25 (15), 4691-4700, 2019 | 493 | 2019 |
| Three-year overall survival with durvalumab after chemoradiotherapy in stage III NSCLC—update from PACIFIC JE Gray, A Villegas, D Daniel, D Vicente, S Murakami, R Hui, T Kurata, ... Journal of Thoracic Oncology 15 (2), 288-293, 2020 | 409 | 2020 |
| Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. DR Spigel, TJ Ervin, R Ramlau, DB Daniel, JH Goldschmidt, ... Journal of Clinical Oncology 29 (15_suppl), 7505-7505, 2011 | 277 | 2011 |
| Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial L Paz-Ares, A Spira, D Raben, D Planchard, BC Cho, M Özgüroğlu, ... Annals of Oncology 31 (6), 798-806, 2020 | 179 | 2020 |
| Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non–small-cell lung cancer DR Spigel, HA Burris III, FA Greco, DL Shipley, EK Friedman, ... Journal of clinical oncology 29 (18), 2582-2589, 2011 | 178 | 2011 |
| Safety, efficacy, and patient-reported health-related quality of life and symptom burden with nivolumab in patients with advanced non–small cell lung cancer, including patients … DR Spigel, M McCleod, RM Jotte, L Einhorn, L Horn, DM Waterhouse, ... Journal of Thoracic Oncology 14 (9), 1628-1639, 2019 | 174 | 2019 |
| Continuous versus 1-year fixed-duration nivolumab in previously treated advanced non–small-cell lung cancer: CheckMate 153 DM Waterhouse, EB Garon, J Chandler, M McCleod, M Hussein, R Jotte, ... Journal of Clinical Oncology 38 (33), 3863, 2020 | 152 | 2020 |
| Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study R Hui, M Özgüroğlu, A Villegas, D Daniel, D Vicente, S Murakami, T Yokoi, ... The Lancet Oncology 20 (12), 1670-1680, 2019 | 146 | 2019 |
| Randomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC) DR Spigel, M McLeod, MA Hussein, DM Waterhouse, L Einhorn, L Horn, ... Annals of Oncology 28, v461, 2017 | 120 | 2017 |
| Myelotoxicity from chemotherapy D Daniel, J Crawford Seminars in oncology 33 (1), 74-85, 2006 | 89 | 2006 |
| IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin+ nab-paclitaxel (CnP) with or without atezolizumab (atezo) as … F Cappuzzo, M McCleod, M Hussein, A Morabito, A Rittmeyer, HJ Conter, ... Annals of Oncology 29, viii742-viii743, 2018 | 87 | 2018 |
| Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive‐stage small cell lung cancer: a multicentre, randomised, double‐blind, placebo … D Daniel, V Kuchava, I Bondarenko, O Ivashchuk, S Reddy, J Jaal, ... International journal of cancer 148 (10), 2557-2570, 2021 | 70 | 2021 |
| Randomized multicenter double-blind placebo-controlled phase II study evaluating MetMAb, an antibody to Met receptor, in combination with erlotinib, in patients with advanced … D Spigel, T Ervin, R Ramlau, D Daniel, J Goldschmidt, M Krzakowski, ... Annals of Oncology 21, 7-7, 2010 | 63 | 2010 |
| Three-year overall survival update from the PACIFIC trial. JE Gray, AE Villegas, DB Daniel, D Vicente, S Murakami, R Hui, T Kurata, ... Journal of Clinical Oncology 37 (15_suppl), 8526-8526, 2019 | 56 | 2019 |
| Effects of trilaciclib on chemotherapy-induced myelosuppression and patient-reported outcomes in patients with extensive-stage small cell lung cancer: pooled results from three … J Weiss, J Goldschmidt, Z Andric, KH Dragnev, C Gwaltney, K Skaltsa, ... Clinical Lung Cancer 22 (5), 449-460, 2021 | 54 | 2021 |
